3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Prolapse
1
Uterine Cervical Neoplasms
1
Surgery
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Menstruation Disturbances
1
Leiomyoma
1
Invasive Breast Carcinoma
1
Endometriosis
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Adenomyosis
1
Interventions
Bevacizumab
21
Paclitaxel
18
Carboplatin
13
pembrolizumab
11
olaparib
10
liposomal doxorubicin
10
Gemcitabine
9
Cyclophosphamide
9
Specimen Handling
8
Topotecan
7
Magnetic Resonance Spectroscopy
7
fludarabine
6
Fulvestrant
6
Taxes
5
Immunoglobulin G
5
Disulfides
5
palbociclib
4
niraparib
4
mirvetuximab soravtansine
4
Oxaliplatin
4
Nivolumab
4
Biopsy
4
trastuzumab deruxtecan
3
ipatasertib
3
cediranib
3
capivasertib
3
atezolizumab
3
aldesleukin
3
Leucovorin
3
Fluorouracil
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Robotic Surgical Procedures
×
30 days
×
Clear all
NCT07120945
2026-06-02
Embrace Gyn
Medtronic - MITG
Phase NA
Active not recruiting
70 enrolled